SG11202104371XA - 1,3,4-oxadiazolone compound and pharmaceutical - Google Patents

1,3,4-oxadiazolone compound and pharmaceutical

Info

Publication number
SG11202104371XA
SG11202104371XA SG11202104371XA SG11202104371XA SG11202104371XA SG 11202104371X A SG11202104371X A SG 11202104371XA SG 11202104371X A SG11202104371X A SG 11202104371XA SG 11202104371X A SG11202104371X A SG 11202104371XA SG 11202104371X A SG11202104371X A SG 11202104371XA
Authority
SG
Singapore
Prior art keywords
pharmaceutical
oxadiazolone compound
oxadiazolone
compound
Prior art date
Application number
SG11202104371XA
Other languages
English (en)
Inventor
Hirotaka KAMITANI
Hisaaki ZAIMOKU
Yoshinari Haruta
Takeo Kikuchi
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of SG11202104371XA publication Critical patent/SG11202104371XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG11202104371XA 2018-11-15 2019-11-14 1,3,4-oxadiazolone compound and pharmaceutical SG11202104371XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018214950 2018-11-15
PCT/JP2019/044615 WO2020100959A1 (ja) 2018-11-15 2019-11-14 １，３，４－オキサジアゾロン化合物及び医薬

Publications (1)

Publication Number Publication Date
SG11202104371XA true SG11202104371XA (en) 2021-05-28

Family

ID=70731909

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104371XA SG11202104371XA (en) 2018-11-15 2019-11-14 1,3,4-oxadiazolone compound and pharmaceutical

Country Status (19)

Country Link
US (1) US20220024921A1 (zh)
EP (1) EP3882239A4 (zh)
JP (1) JP7434172B2 (zh)
KR (1) KR20210091767A (zh)
CN (1) CN113302184A (zh)
AU (1) AU2019381493A1 (zh)
BR (1) BR112021009198A2 (zh)
CA (1) CA3117550A1 (zh)
CL (1) CL2021001275A1 (zh)
CO (1) CO2021007442A2 (zh)
EA (1) EA202191349A1 (zh)
EC (1) ECSP21034281A (zh)
IL (1) IL282999A (zh)
MA (1) MA54243A (zh)
MX (1) MX2021005566A (zh)
PE (1) PE20211283A1 (zh)
PH (1) PH12021551103A1 (zh)
SG (1) SG11202104371XA (zh)
WO (1) WO2020100959A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117285459B (zh) * 2023-11-24 2024-02-27 上海美迪西生物医药股份有限公司 一种小分子激酶抑制剂化合物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01139581A (ja) * 1987-08-20 1989-06-01 Nissan Chem Ind Ltd テトラヒドロフタルイミド誘導体、その製法および除草剤
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
US20090105221A1 (en) 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
CN101084191A (zh) 2004-12-22 2007-12-05 默克公司 用于制备取代哌啶类化合物的方法
JP2011515337A (ja) 2008-02-29 2011-05-19 サイレーン ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼモジュレーター
GB0813740D0 (en) 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
EP2796456A1 (en) 2010-12-09 2014-10-29 Amgen Inc. Bicyclic compounds as Pim inhibitors
AU2012230890A1 (en) * 2011-03-22 2013-09-26 Amgen Inc. Azole compounds as Pim inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
RU2014151009A (ru) 2012-06-07 2016-08-10 Ф. Хоффманн-Ля Рош Аг Пиразолопиримидоновые и пиразолопиридоновые ингибиторы танкиразы
GB201814151D0 (en) * 2018-08-31 2018-10-17 Ucl Business Plc Compounds

Also Published As

Publication number Publication date
ECSP21034281A (es) 2021-06-30
MX2021005566A (es) 2021-07-15
PH12021551103A1 (en) 2021-11-22
EP3882239A4 (en) 2022-08-10
EA202191349A1 (ru) 2021-08-10
JP7434172B2 (ja) 2024-02-20
CO2021007442A2 (es) 2021-06-21
IL282999A (en) 2021-06-30
WO2020100959A1 (ja) 2020-05-22
MA54243A (fr) 2021-09-22
PE20211283A1 (es) 2021-07-19
JPWO2020100959A1 (ja) 2021-10-07
CA3117550A1 (en) 2020-05-22
KR20210091767A (ko) 2021-07-22
EP3882239A1 (en) 2021-09-22
CN113302184A (zh) 2021-08-24
BR112021009198A2 (pt) 2021-08-03
US20220024921A1 (en) 2022-01-27
AU2019381493A1 (en) 2021-06-03
TW202031649A (zh) 2020-09-01
CL2021001275A1 (es) 2021-11-05

Similar Documents

Publication Publication Date Title
GB2569961B (en) Pharmaceutical
IL288816A (en) Aminobenzazepine compounds, immunoconjugates and uses thereof
GB2572126B (en) Pharmaceutical
GB2572125B (en) Pharmaceutical
SG11202011685QA (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
IL278877B1 (en) Amino-pyrazinecarboxamide compounds, conjugates and their uses
IL283539A (en) 3,3-difluoroallylamines or their salts and pharmaceutical preparations containing them
PT3580208T (pt) Derivados de 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ol e compostos relacionados como inibidores de prs para tratamento de, por exemplo, cancro
IL276952A (en) History of 4,2-diaminoquinazolines and their medicinal uses
IL272055A (en) 8,1-naphthyridinone compounds and their uses
IL278142A (en) Antiproliferative compounds and their uses
IL276753A (en) Epibrotic compounds, their devices and uses
IL284765A (en) 8,1-naphthyridinone compounds and their uses
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
IL276783A (en) The composition and pharmaceutical compound containing it
IL282999A (en) 4,3,1-oxadiazolone compound and drug
EP3715344A4 (en) 1,4-BENZODIAZAPINE-2-ON DERIVATIVES AND THEIR USES
IL282142A (en) The history of 4-pyrazine-2-ylmethyl-morpholine and its use as a medicine
EP4082614A4 (en) ACYLSULFAMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF
GB201819687D0 (en) Mrbr.5